Prelude Capital Management’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q4 | – | Sell |
-45,148
| Closed | -$506K | – | 1958 |
|
|
2017
Q3 | $506K | Buy |
45,148
+39,027
| +638% | +$431K | 0.05% | 375 |
|
|
2017
Q2 | $67K | Sell |
6,121
-18,551
| -75% | -$186K | 0.01% | 905 |
|
|
2017
Q1 | $242K | Buy |
24,672
+17,527
| +245% | +$175K | 0.02% | 503 |
|
|
2016
Q4 | $77K | Sell |
7,145
-12,755
| -64% | -$128K | 0.01% | 910 |
|
|
2016
Q3 | $204K | Buy |
19,900
+14,300
| +255% | +$156K | 0.02% | 558 |
|
|
2016
Q2 | $73K | Sell |
5,600
-400
| -7% | -$5.24K | 0.01% | 869 |
|
|
2016
Q1 | $66K | Sell |
6,000
-14,000
| -70% | -$124K | 0.01% | 896 |
|
|
2015
Q4 | $184K | Buy |
20,000
+11,300
| +130% | +$94.6K | 0.03% | 610 |
|
|
2015
Q3 | $60K | Buy |
8,700
+2,400
| +38% | +$20.6K | 0.01% | 1006 |
|
|
2015
Q2 | $62K | Buy |
6,300
+5,000
| +385% | +$45.5K | 0.01% | 1081 |
|
|
2015
Q1 | $12K | Buy |
+1,300
| New | +$10.4K | ﹤0.01% | 1815 |
|
|
2014
Q4 | – | Sell |
-8,816
| Closed | -$61K | – | 2318 |
|
|
2014
Q3 | $61K | Buy |
8,816
+2,916
| +49% | +$17.5K | 0.01% | 1322 |
|
|
2014
Q2 | $31K | Buy |
+5,900
| New | +$28.7K | ﹤0.01% | 1636 |
|
Prelude Capital Management's SCLN Position: Q4 2017 in Review
Prelude Capital Management sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q4 2017, closing a stake of 45,148 shares — an estimated $506K sold.
Prelude Capital Management first reported a position in SCLN in Q2 2014 and held it in 13 quarters. The position peaked at $506K in Q3 2017. 0 funds tracked by Wall St. Rank hold SCLN as of Q4 2017.
- Prelude Capital Management reported no remaining Sciclone Pharmaceuticals Inc position as of Q4 2017 after selling out during the quarter.
- Prelude Capital Management sold 45,148 Sciclone Pharmaceuticals Inc shares in Q4 2017, an estimated $506K.
- Prelude Capital Management first reported a position in Sciclone Pharmaceuticals Inc in Q2 2014 and held it in 13 quarters.
- Prelude Capital Management's Sciclone Pharmaceuticals Inc position peaked at $506K in Q3 2017.
- 0 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q4 2017.
Based on Prelude Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.